Gracell: FDA OKs Application for Phase 1/2 Trial of FasTCAR-T GC012F for Lupus Erythematosus

 Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-cells  

FasTCAR-T GC012F has demonstrated deep responses and a favorable safety profile in clinical investigator-initiated trials (IIT) in 60 patients with multiple myeloma and B-cell non-Hodgkin lymphoma (B-NHL)

https://www.biospace.com/article/releases/gracell-biotechnologies-announces-fda-clearance-of-ind-application-for-phase-1-2-clinical-trial-of-fastcar-t-gc012f-for-the-treatment-of-refractory-systemic-lupus-erythematosus/